WHITEHOUSE STATION, N.J.—Increasing generic competition and pricing pressures united two more of the world’s largest pharmaceutical players this week, as Merck & Co. announced on Monday it will buy Schering-Plough in a $41.1 billion stock-and-cash deal that some industry veterans are calling “the mating of dinosaurs.”